Literature DB >> 12353835

Liver pathology and cell proliferation after octreotide administration following partial hepatectomy in rats: an experimental study.

Efstathios Papalampros, Evangelos S Felekouras, Konstantinos Filis, Roxanne Angelopoulou, Theodore Kourelis, Athanassios C Tsamandas, Elias Bastounis.   

Abstract

Octreotide is a somatostatin analog introduced for clinical use that inhibits the growth of various tumors in rats. This study investigates liver pathology after octreotide treatment following partial (2/3) hepatectomy in rats. Thirty rats, weighing 250-300 g underwent partial hepatectomy and were divided in to two groups. Group A (N = 25) received octreotide subcutaneously [2 microg Sandostatin (Sandoz) in 1 ml normal saline every 12 hr for 15 days]. Group B (N = 5) was injected with 1 ml normal saline subcutaneously every 12 hr for the same time period; animals in this group were used as controls. At the end of the experiment rats were sacrificed and liver tissue was obtained for pathologic examination. Liver sections from group A (octreotide administration) showed extensive cholangiolar and fibrous tissue proliferation in the hepatectomy area, and hypertrophy and swelling of Kupffer cells in the liver parenchyma. Sections from the hepatectomy surface from group B (controls) displayed signs of liver regeneration. Proliferation activity (Ki-67+ cells) was higher in the cholangiolar epithelium in group A and in hepatocytes in group B. In conclusion, the results of this study show that octreotide inhibits liver regeneration, which occurs after partial hepatectomy in rats and enhances hyperplasia of cholangiolar and fibrous tissue.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12353835     DOI: 10.1023/a:1019687804859

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  17 in total

Review 1.  The role of somatostatin and its analogs in the diagnosis and treatment of tumors.

Authors:  S W Lamberts; E P Krenning; J C Reubi
Journal:  Endocr Rev       Date:  1991-11       Impact factor: 19.871

2.  The enhancement of tumor growth after partial hepatectomy and the effect of sera obtained from hepatectomized rats on tumor cell growth.

Authors:  T Asaga; K Suzuki; M Umeda; Y Sugimasa; S Takemiya; T Okamoto
Journal:  Jpn J Surg       Date:  1991-11

3.  Depressed liver regeneration after partial hepatectomy of germ-free, athymic and lipopolysaccharide-resistant mice.

Authors:  R P Cornell; B L Liljequist; K F Bartizal
Journal:  Hepatology       Date:  1990-06       Impact factor: 17.425

4.  Effects of octreotide on liver regeneration and tumour growth in the regenerating liver.

Authors:  N Davies; J Yates; H Kynaston; B A Taylor; S A Jenkins
Journal:  J Gastroenterol Hepatol       Date:  1997-01       Impact factor: 4.029

5.  Endotoxin modulation of hepatocyte secretory and cellular protein synthesis is mediated by Kupffer cells.

Authors:  M A West; T R Billiar; J E Mazuski; R J Curran; F B Cerra; R L Simmons
Journal:  Arch Surg       Date:  1988-11

6.  The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients.

Authors:  S W Lamberts; R Oosterom; M Neufeld; E del Pozo
Journal:  J Clin Endocrinol Metab       Date:  1985-06       Impact factor: 5.958

7.  Reticuloendothelial stimulation: levamisole compared.

Authors:  N Davies; H Kynaston; J Yates; D M Nott; S A Jenkins; B A Taylor
Journal:  Dis Colon Rectum       Date:  1993-11       Impact factor: 4.585

8.  Heterogeneity in hepatic transport of somatostatin analog octapeptides.

Authors:  G Fricker; V Dubost; D Schwab; C Bruns; C Thiele
Journal:  Hepatology       Date:  1994-07       Impact factor: 17.425

Review 9.  Kupffer cells and liver metastasis. Optimization and limitation of activation of tumoricidal activity.

Authors:  N C Phillips
Journal:  Cancer Metastasis Rev       Date:  1989-12       Impact factor: 9.264

10.  Octreotide, the reticuloendothelial system, and experimental liver tumour.

Authors:  N Davies; H Kynaston; J Yates; B A Taylor; S A Jenkins
Journal:  Gut       Date:  1995-04       Impact factor: 23.059

View more
  4 in total

1.  Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials.

Authors:  Tian-Kang Guo; Xiang-Yong Hao; Bin Ma; Ke-Hu Yang; Yi-Ping Li; Hong-Ling Li; Yuan-Hui Gu; Hui Cai; Ya-Li Liu; Yuan Li; Wei-Peng Zhan
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-18       Impact factor: 4.553

2.  A Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or Higher.

Authors:  Usman Shah; Bert O'Neil; Jill Allen; Richard M Goldberg; Steven Bernard; Dominic Moore; Alan P Venook; Michael M Morse
Journal:  Gastrointest Cancer Res       Date:  2009-03

Review 3.  Somatostatin and the "Small-For-Size" Liver.

Authors:  Amelia J Hessheimer; Lilia Martínez de la Maza; Farah Adel Al Shwely; Arlena Sofía Espinoza; Fabio Ausania; Constantino Fondevila
Journal:  Int J Mol Sci       Date:  2019-05-22       Impact factor: 5.923

4.  Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma.

Authors:  Lynn G Feun; Medhi Wangpaichitr; Ying-Ying Li; Deukwoo Kwon; Stephen P Richman; Peter J Hosein; Niramol Savaraj
Journal:  J Hepatocell Carcinoma       Date:  2018-01-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.